Common antidepressant can treat long COVID fatigue symptoms: study
March 30, 2026
March 30, 2026
A common and low-cost antidepressant can successfully treat fatigue associated with long COVID, according to a new study.
Co-led by researchers from McMaster University in Ontario, the study found that the drug fluvoxamine, which is commonly sold under the name Luvox, significantly reduced fatigue symptoms in a clinical trial of 399 adults with long COVID. It is one of the first times a medication has been shown to effectively treat the condition.
“This is an important step forward for patients who have been desperate for evidence‑based options,” senior author and McMaster University professor Edward Mills said in a news release.
“Fluvoxamine showed consistent and meaningful benefits, and because it’s already widely used and well understood, it has clear potential for clinical use.”
Mainstream NewsBed Bug Infestation Forces Closure of Fort Simpson Schools
Two schools in Fort Simpson, N.W.T., will close starting Monday due to a bed bug infestation, with no confirmed reopening date.
Mainstream NewsThe Complex History of Bible Translations in Greenland and Labrador
Early Christian missionaries in Greenland and Labrador relied on Inuit converts to translate the Bible, revealing a complex interplay of cultural exchange and religious adaptation.
Mainstream NewsInuit-Led Pirutsiagutiit Program Replaces Child First Initiative
Federal government transfers $575M in child health and social support funding to Inuit organizations, ending uncertainty over previous program.
Mainstream NewsWhitehorse Students Engage With Canadian Astronauts Aboard the ISS
Students from Whitehorse schools connected with Canadian astronauts Jenni Gibbons and Joshua Kutryk, gaining insights into space exploration and inspiring future careers in science.